Paeds Cases · haematology-oncology-and-transfusion
Brain and spinal tumours: Case
Clinical long case of a seven-year-old girl presenting with progressive early morning headache, vomiting, a new squint and ataxia from a posterior fossa medulloblastoma with obstructive hydrocephalus, covering the recognition of raised intracranial pressure, the urgent magnetic resonance imaging of the brain and whole neuraxis, the perioperative stabilisation with dexamethasone and the management of hydrocephalus, the maximal safe resection and the molecular risk stratification, the risk-adapted craniospinal irradiation and chemotherapy, and the long-term survivorship plan.
On this page
Study tools
Target exams
Framing the case
This seven-year-old girl has the classic presentation of a posterior fossa tumour with obstructive hydrocephalus. The progressive early morning headache that wakes her from sleep, the vomiting that relieves it, the papilloedema, the false-localising right sixth palsy, and the truncal ataxia with the dysmetria, together make a posterior fossa mass the working diagnosis, and the first decision is to move the child from an elective workup to an emergency resuscitation. The framework that organises the case is the location, the posterior fossa, and the biology, the embryonal medulloblastoma that is the commonest malignant brain tumour of childhood. [2][3]
Immediate assessment and stabilisation
The assessment begins with the airway, the breathing and the circulation, and the level of consciousness, because a drowsy child with the papilloedema and the ataxia is at risk of the herniation from the unrelieved hydrocephalus. The child is admitted to a paediatric neuro-oncology centre, and the dexamethasone is started at zero point one to zero point two milligrams per kilogram per dose every six hours to control the vasogenic oedema. The head is elevated, the isotonic fluids are maintained, and the neurosurgical and the oncology teams are alerted. The hydrocephalus is managed with the external ventricular drain at the surgery or before it, because the obstructed cerebrospinal fluid pathway is the immediate threat. [11]
The diagnostic pathway
The magnetic resonance imaging of the brain with and without contrast confirms the posterior fossa mass, the oedema, the hydrocephalus and the relationship to the fourth ventricle and the brainstem. The whole neuraxis is imaged at the diagnosis because the medulloblastoma disseminates through the cerebrospinal fluid, and the spinal magnetic resonance shows no drop metastases. The cerebrospinal fluid cytology, sent once the pressure is relieved, shows no malignant cells. The maximal safe resection is performed, and the residual tumour on the postoperative scan measures under one point five square centimetres. The histology confirms the medulloblastoma, and the molecular studies place it in the molecularly average-risk category. [3][4]
References6ShowHide
- [2]Pollack IF, Agnihotri S, Broniscer A Childhood brain tumors: current management, biological insights, and future directions J Neurosurg Pediatr, 2019.PMID 30835699
- [3]Northcott PA, Robinson GW, Kratz CP Medulloblastoma Nat Rev Dis Primers, 2019.PMID 30765705
- [4]Taylor MD, Northcott PA, Korshunov A Molecular subgroups of medulloblastoma: the current consensus Acta Neuropathol, 2012.PMID 22134537
- [7]van den Bent M, Saratsis AM, Geurts M H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions Neuro Oncol, 2024.PMID 38102230
- [11]Malbari F, Staggers KA, Minard CG Provider views on perioperative steroid use for patients with newly diagnosed pediatric brain tumors J Neurooncol, 2020.PMID 32026434
- [12]Rey-Casserly C, Diver T Late effects of pediatric brain tumors Curr Opin Pediatr, 2019.PMID 31693589